Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer
- 203 Downloads
To observe the dynamic changes of blood perfusion and hypoxic status with CT perfusion imaging and hypoxia imaging in patients of non-small-cell lung cancer (NSCLC) who were treated with recombinant human endostatin (RHES).
Fifteen previously untreated patients with histologically or cytologically confirmed NSCLC were enrolled. They were randomly divided into research group (n=10) and negative control group (n=5). The patients of the research group continuously used RHES for ten days, and simultaneously had CT perfusion imaging and hypoxia imaging performed on days 1, 5 and 10, respectively. The remaining 5(control) only had CT perfusion imaging and hypoxia imaging, without using RHES, on days 1, 5 and 10, respectively. According to the above results, we could obtain a “time window” during which RHES improves blood perfusion and hypoxia of lung cancer.
In the research group, after using RHES, capillary permeability surface (PS) and tumour to normal tissue (T/N) decreased at first, and then increased. Their lowest points occurred on about the fifth day with statistical significance compared with the first day (T/N, p=0.00; PS, p<0.01). Blood flow (BF) was first increased and then decreased. Its highest point occurred on about the fifth day with statistical significance compared with the first and tenth day (all p<0.01). The PS, BF and T/N peaked on the fifth day in the research group with statistical significance compared with the negative control group as well (all p<0.01). The above results suggested that RHES’s “time window” was within about one week after administration.
RHES’s “time window” is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in human tumours.
KeywordsRecombinant human endostatin Hypoxia imaging Non-small-cell lung cancer CT perfusion imaging
Unable to display preview. Download preview PDF.
- 3.Peng F, Wang J, Zou Y et al (2011) Recombinant human endostatin improves tumor vasculature and alleviates hypoxia in Lewis lung carcinoma. Chin J Radiat Oncol 20:69–72Google Scholar
- 7.Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29[6 Suppl 16]:15–18Google Scholar
- 9.Wang J-W, Sun Y, Liu Y-Y et al (2005) Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Oncol 8:283–290Google Scholar
- 10.Ling CH, Ji C, Chen YB et al (2004) Combined effects of endostatin gene transfer and ionizing radiation on lung adenocarcinoma model of A549 cells. Chin J Tuberc Respir Dis 27:683–686Google Scholar